Logo image of ISPR

ISPIRE TECHNOLOGY INC (ISPR) Stock Fundamental Analysis

NASDAQ:ISPR - Nasdaq - US46501C1009 - Common Stock - Currency: USD

2.7925  -0.4 (-12.46%)

Fundamental Rating

2

Overall ISPR gets a fundamental rating of 2 out of 10. We evaluated ISPR against 8 industry peers in the Tobacco industry. ISPR has a bad profitability rating. Also its financial health evaluation is rather negative. ISPR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ISPR had negative earnings in the past year.
In the past year ISPR has reported a negative cash flow from operations.
ISPR Yearly Net Income VS EBIT VS OCF VS FCFISPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 5M -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.08%, ISPR is doing worse than 75.00% of the companies in the same industry.
ISPR has a Return On Equity (-188.51%) which is in line with its industry peers.
Industry RankSector Rank
ROA -24.08%
ROE -188.51%
ROIC N/A
ROA(3y)-6.85%
ROA(5y)N/A
ROE(3y)-25.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISPR Yearly ROA, ROE, ROICISPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

The Gross Margin of ISPR (21.24%) is worse than 62.50% of its industry peers.
In the last couple of years the Gross Margin of ISPR has grown nicely.
ISPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.08%
GM growth 5YN/A
ISPR Yearly Profit, Operating, Gross MarginsISPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 5 -5 10 15

More info and screens

3

2. Health

2.1 Basic Checks

ISPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ISPR has been increased compared to 1 year ago.
There is no outstanding debt for ISPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ISPR Yearly Shares OutstandingISPR Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M 50M
ISPR Yearly Total Debt VS Total AssetsISPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ISPR has an Altman-Z score of 1.15. This is a bad value and indicates that ISPR is not financially healthy and even has some risk of bankruptcy.
ISPR has a Altman-Z score (1.15) which is in line with its industry peers.
ISPR has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
ISPR has a Debt to Equity ratio of 0.08. This is in the better half of the industry: ISPR outperforms 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 1.15
ROIC/WACCN/A
WACC10.11%
ISPR Yearly LT Debt VS Equity VS FCFISPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 0.98 indicates that ISPR may have some problems paying its short term obligations.
With a decent Current ratio value of 0.98, ISPR is doing good in the industry, outperforming 62.50% of the companies in the same industry.
A Quick Ratio of 0.90 indicates that ISPR may have some problems paying its short term obligations.
The Quick ratio of ISPR (0.90) is better than 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.9
ISPR Yearly Current Assets VS Current LiabilitesISPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ISPR have decreased strongly by -133.79% in the last year.
Looking at the last year, ISPR shows a decrease in Revenue. The Revenue has decreased by -1.69% in the last year.
The Revenue has been growing by 33.80% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-133.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.97%
Revenue 1Y (TTM)-1.69%
Revenue growth 3Y33.8%
Revenue growth 5YN/A
Sales Q2Q%-12.74%

3.2 Future

ISPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.89% yearly.
Based on estimates for the next years, ISPR will show a quite strong growth in Revenue. The Revenue will grow by 16.38% on average per year.
EPS Next Y-76.27%
EPS Next 2Y17.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.05%
Revenue Next 2Y16.38%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ISPR Yearly Revenue VS EstimatesISPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M
ISPR Yearly EPS VS EstimatesISPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ISPR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISPR Price Earnings VS Forward Price EarningsISPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISPR Per share dataISPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as ISPR's earnings are expected to grow with 17.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.89%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ISPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ISPIRE TECHNOLOGY INC

NASDAQ:ISPR (7/2/2025, 3:40:30 PM)

2.7925

-0.4 (-12.46%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)05-09 2025-05-09/amc
Earnings (Next)09-24 2025-09-24/bmo
Inst Owners8.91%
Inst Owner Change-5.91%
Ins Owners4.08%
Ins Owner Change0.58%
Market Cap159.59M
Analysts82.86
Price Target7.65 (173.95%)
Short Float %3.16%
Short Ratio10.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-75.65%
Min EPS beat(2)-96.08%
Max EPS beat(2)-55.23%
EPS beat(4)1
Avg EPS beat(4)-45.02%
Min EPS beat(4)-96.08%
Max EPS beat(4)34.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-6.58%
Min Revenue beat(2)-19.25%
Max Revenue beat(2)6.1%
Revenue beat(4)2
Avg Revenue beat(4)-7.9%
Min Revenue beat(4)-25.34%
Max Revenue beat(4)6.9%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.67%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.1
P/FCF N/A
P/OCF N/A
P/B 10.79
P/tB 12.58
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS2.53
BVpS0.26
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.08%
ROE -188.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.24%
FCFM N/A
ROA(3y)-6.85%
ROA(5y)N/A
ROE(3y)-25.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.08%
GM growth 5YN/A
F-Score3
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.28%
Cap/Sales 1.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.9
Altman-Z 1.15
F-Score3
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)1179.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-133.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.97%
EPS Next Y-76.27%
EPS Next 2Y17.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.69%
Revenue growth 3Y33.8%
Revenue growth 5YN/A
Sales Q2Q%-12.74%
Revenue Next Year0.05%
Revenue Next 2Y16.38%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-166.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-62.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-126.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.45%
OCF growth 3YN/A
OCF growth 5YN/A